There is potentially big news in America’s war on Alzheimer’s.
Eli Lilly reports that its treatment donanemab significantly slowed progression of the mind-robbing disease.
The company reported on a positive clinical test.
Patients showed a 35% slower decline in memory, thinking and their ability to perform daily activities compared with those who did not receive the treatment, Eli Lilly said.
